tbuckley/cabot-search huggingface dataset:
Effect of Graft Source and Transplant Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Mantle Cell Lymphoma (MCL): A Cibmtr Analysis
Authors: Mehdi Hamadani, Wael Saber, Jeanette Carreras, Kwang W Ahn, Ginna G Laport, Silvia Montoto, David G. Maloney, Hillard M Lazarus
Journal: Blood (2012)
Expression of the Cancer-Testis Antigens, SEMG 1 and Protamine 1, in Early CLL: Their Relationship to Disease Stage and Zap 70 Expression.
Authors: Farouk Meklat, Yana Zhang, Zhiqing Wang, Jian Zhang, Sukhrob Mustalov, Andrew P. Jewell, Seah H. Lim
Journal: Blood (2007)
The Lumleian Lectures on some Cirrhoses of the Liver: Delivered before the Royal College of Physicians
Authors: W. B. Cheadle
Journal: BMJ (1900)

CIRRHOSIS Of the liver occurs in various forms, and in different degrees.It does not, as some would appear to conceive, arise suddenly fully developed-in the extreme form of the final stage of atrophic degeneration.It is my purpose to deal
Longer Duration of Thalidomide Monotherapy Results in Improved Outcome in Relapsed/Refractory Multiple Myeloma.
Authors: Marie von Lilienfeld-Toal, Corinna Hahn-Ast, Francesco Bertolini, Jelena Bila, Mathieu Boulin, Heather Oakervee, Teresa Cibeira, Gordon Cook, Anna Dmoszynska, Roland Fenk, Tommasina Guglielmelli, Hartmut Goldschmidt, Yukata Hattori, Bethan Myers, Massimo Offidani, Francesca Patriarca, Maria Teresa Petrucci, Massimo Pini, Miles Prince, Steve Schey, Pieter Sonneveld, Ibrahim Yakoub-Agha, Anders Waage, Axel Glasmacher
Journal: Blood (2007)
Food Insecurity and “Unexplained” Weight Loss
Authors: Hilary Kessler Seligman
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Patient-Reported Quality of Life Is an Independent Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation: A Secondary Analysis from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902
Authors: William A. Wood, Jennifer Le-Rademacher, Mingwei Fei, Brent R. Logan, Karen L Syrjala, Navneet S. Majhail, John R. Wingard, Muneer H. Abidi, Nancy L. Geller, Juan Wu, J. Douglas Rizzo, Edward A Faber, Heather Jim, Paul Jacobsen, Mary M. Horowitz, Stephanie J. Lee
Journal: Blood (2014)
Combined Effects of a Pan-ABL1 Kinase Inhibitor, Ponatinib and Dasatinib Against T315I Mutant Forms of BCR-ABL1: In Vitro and In Vivo Studies
Authors: Tetsuzo Tauchi, Seiichiro Katagiri, Seiichi Okabe, Eishi Ashihara, Shinya Kimura, Taira Maekawa, Kazuma Ohyashiki
Journal: Blood (2011)
The inducible cyclic adenosine 3’,5’-monophosphate early repressor (ICER) enhances drug sensitivity in acute myeloid leukemia
Authors: M. Pigazzi, E. Manara, E. Baron, A. Beghin, G. Basso
Journal: Journal of Clinical Oncology (2009)

e22045 Background: The Inducible Cyclic Adenosine 3’,5’-monophosphate early repressor (ICER) is a transcription factor that principally counteracts the cAMP response element binding protein (CREB) activity. CREB was previously demonstrated to be overexpressed in acute leukemia, whereas ICER was found rapidly degradated being unable to control gene transcription. ICER exogenous expression was demonstrated to repress CREB targets preventing leukemia progression. We hypothesized that ICER restoration deserves a special consideration for playing a role in CREB oncogenic feature and in modeling leukemic cell phenotype. Methods: We constructed an expression vector for ICER and induced its exogenous expression in HL60 cells (HL60+ICER). We monitored transcription and translation of a series of genes involved in different pathways by quantitative gene expression and western blot analysis. We investigate ICER's role in cell death after treatment with chemotherapic drugs. Results: We revealed that ICER was able to control gene expression in leukemia, principally of genes involved in cell death and survival. In particular, we focused on DUSP1 and DUSP4 phosphatases which were found significantly repressed. HL60+ICER after being treated with drugs increased apoptosis. Cell cycle analyses revealed a block in G2 phase, a lowered cell proliferation and clonogenic potential with respect to HL60 treated at the same conditions. DUSPs downstream targets (IL6, RB, RAS) were lowered expressed and p38 constitutively phosphorylated confirming their role in mediating cellular stress. ICER driven apoptosis was found to be caspases mediated. An enhanced activity of p38 was observed in treated HL60+ICER, and by the use of specific p38 inhibitors apoptosis decreased. Other possible apoptotic pathways (AKT, ERK, JNK) were excluded because found severely disrupted. Conclusions: Finally, we described an enhanced sensibility to drugs in HL60 induced by ICER exogenous expression and that p38 stress signaling pathway is the direct target of this phenomenon. The ability of ICER to modify leukemic cells phenotype respect to chemotherapeutic treatment gave an important information for targets and therapeutic possibilities. No significant financial relationships to disclose.
Exosomes Generated From iPSC-Derivatives
Authors: Ji-Hye Jung, Xuebin Fu, Phillip C. Yang
Journal: Circulation Research (2017)

Cardiovascular disease (CVD) is the leading cause of death in modern society. The adult heart innately lacks the capacity to repair and regenerate the damaged myocardium from ischemic injury. Limited understanding of cardiac tissue repair process hampers the development of effective therapeutic solutions to treat CVD such as ischemic cardiomyopathy. In recent years, rapid emergence of induced pluripotent stem cells (iPSC) and iPSC-derived cardiomyocytes presents a valuable opportunity to replenish the functional cells to the heart. The therapeutic effects of iPSC-derived cells have been investigated in many preclinical studies. However, the underlying mechanisms of iPSC-derived cell therapy are still unclear, and limited engraftment of iPSC-derived cardiomyocytes is well known. One facet of their mechanism is the paracrine effect of the transplanted cells. Microvesicles such as exosomes secreted from the iPSC-derived cardiomyocytes exert protective effects by transferring the endogenous molecules to salvage the injured neighboring cells by regulating apoptosis, inflammation, fibrosis, and angiogenesis. In this review, we will focus on the current advances in the exosomes from iPSC derivatives and discuss their therapeutic potential in the treatment of CVD.
Clonal Analysis of Progressive Maturation of Erythroid Cells from Human Embryonic Stem Cell-Derived Definitive Hematopoiesis.
Authors: Feng Ma, Yasuhiro Ebihara, Katsutsugu Umeda, Hiromi Sakai, Sachiyo Hanada, Hong Zhang, Eishun Tsuchida, Tatsutoshi Nakahata, Hiromitsu Nakauchi, Kohichiro Tsuji
Journal: Blood (2007)
Activation of the mTOR Signaling Pathway by L-Leucine in RPS14-Deficient Erythroid Cells
Authors: Bon Ham Yip, Chaitanya Vuppusetty, Andrea Pellagatti, Aristoteles Giagounidis, Ulrich Germing, Abigail A Lamikanra, David J Roberts, Marta Fernandez-Mercado, Emma-Jane McDonald, Cristina Mecucci, Sally Killick, James S Wainscoat, Jacqueline Boultwood
Journal: Blood (2012)
The Stage-Modified IPI (MIPI), Histology and a Combined Treatment Influence the Clinical Outcome of 401 Patients with Primary Extranodal Head and Neck B-Cell Lymphomas (PHNBCL) (IELSG 23).
Authors: Sergio Cortelazzo, Andrea Rossi, Massimo Federico, Andrea Peveri, Stefano Magrini, Maurizio Martelli, Armando Lopez Guillermo, Elena Oldani, Alessandro Rambaldi, Fausto Rossini, Enrico M. Pogliani, Emanuele Zucca, Annarita Conconi, Mario Busetto, Gianluca Gaidano, Tiziano Barbui, Franco Cavalli
Journal: Blood (2005)
Successful Engraftment of Autologous CD34+ Stem Cells after High-Dose Therapy and Fixed Dose (6 mg) Pegfilgrastim.
Authors: Gianpaolo Marcacci, Maria C. Petti, Felicetto Ferrara, Sergio Storti, Giovanni D’Arena, Francesca Palombi, Salvatore Palmieri, Giulio Giordano, Antonio Pinto
Journal: Blood (2005)
Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies
Authors: Mark Haas, James Mirocha, Nancy L. Reinsmoen, Ashley A. Vo, Jua Choi, Joseph M. Kahwaji, Alice Peng, Rafael Villicana, Stanley C. Jordan
Journal: Kidney International (2017)
Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique Quiescent-Cell Selective Cytotoxicity.
Authors: Francis Y. Lee, Mei-Li Wen, Amy Camuso, Stephen Castenada, Krista Fager, Christine Flefleh, Ivan Inigo, Roger Luo, David Kan, Veeraswamy Manne, Kelly McGlinchey, Richard Smykla, Roberto Weinmann, Robert Kramer
Journal: Blood (2005)
Post-Marketing Assessments of Serious Adverse Drug Reactions Reported by the Manufacturer to the FDA Differ Markedly with Those from an Independent Pharmacovigilance Program: Empirical Findings Based on Bisphosphonate-Associated Osteonecrosis Descriptions by the Research on Adverse Events and Reports Project and the Product Manufacturer.
Authors: Victoria Kut, J. Mehta, S. Singhal, C. Bennett
Journal: Blood (2004)
BMET-29. HER2 STATUS OF BRAIN METASTASES IN GASTRIC AND GASTROESOPHAGEAL ADENOCARCINOMA
Authors: Omer Gal-Katziri, Shlomit Yust-Katz, Tali Siegal, Dror Limon
Journal: Neuro-Oncology (2016)

Brain metastases in (BM) gastric and gastroesophageal adenocarcinoma (GAD) are relatively rare. Improvement in treatment has led to an increased survival and higher incidence of brain metastases. HER2 amplification is found in about 20% of GAD patients. In other cancers, including breast cancer, HER2 amplification and overexpression are associated with an increased risk of BM. In GAD patients the association is not yet clear. In this retrospective study, we searched the institutional database for patients with GAD brain metastases diagnosed between 2008-2015. Demographic characteristic as well as HER2 status were collected for all patients. 393 patients with a confirmed diagnosis of GAD were identified. HER2 results were available from 2011 for 156 patients. HER2 overexpression or amplification was found in 41 patients (26%). 16/393 patients (4.1%) developed brain metastases and for 10 patients we have confirmed HER2 results, while the rest are currently under revision. Of the 10 patients, 6 were negative for HER2 overexpression or amplification and 4 were positive. The median survival of the 16 patients with BM was 15.8 mos. No difference in survival from time of diagnosis was found between HER2 positive (n=4) and Her2 negative group (n=6) (18.5 vs. 14.2 respectively, p=0.67). Median time from diagnosis to development of BM was 13.6 mo. for all the patients, with no difference by HER2 status (pos. 13.1 mo. vs. neg. 14.2 mo.). Median survival from the time of BM diagnosis was 2.4 mos. BM in GAD are a rare event, found in about 4% of GAD patients. HER2 positivity was slightly more common in the BM group than in the general GAD population. HER2 positivity did not affect survival when compared to the HER2 negative group. Updated results for HER2 status of our series of BM will be presented.
Molecular Mechanism Regulating Foxo In Leukemia Initiating Cells of Chronic Myeloid Leukemia.
Authors: Kazuhito Naka, Takayuki Hoshii, Yuko Tadokoro, Takako Ooshio, Yukio Kondo, Shinji Nakao, Noboru Motoyama, Atsushi Hirao
Journal: Blood (2010)
Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.
Authors: Srdan Verstovsek, Ayalew Tefferi, Steven Kornblau, Deborah Thomas, Jorge Cortes, Farhad Ravandi-Kashani, Guillermo Garcia-Manero, Hagop Kantarjian
Journal: Blood (2007)
Targeting the Leukemia-Associated Hypoxic Microenvironment with Hypoxia-Activated Prodrug PR-104
Authors: Juliana Benito, Yuexi Shi, Barbara Szymanska, Hernan Carol, Ingrid Bohem, Hongbo Lu, Sergej Konoplev, Wendy Fang, Steven M. Kornblau, Patrick Zweidler-McKay, William Wilson, Dario Campana, Gautam Borthakur, Carlos E. Bueso-Ramos, Hagop M. Kantarjian, Elizabeth J. Shpall, Deborah A Thomas, Craig T. Jordan, Richard B Lock, Michael Andreeff, Marina Konopleva
Journal: Blood (2010)
Retrospective Investigation of Hemostatic Complications In 423 Patients Receiving Hematopoietic Stem-Cell Transplantation (HSCT).
Authors: Yue Han, Wu Depei, Luping Hu, Lili Zhou, Yongya Ren, Wei Zhang, Xiaojin Wu, Xiaohui Hu, Xiang Zhang, Zhaoyue Wang, Changgeng Ruan
Journal: Blood (2010)
SIRT1 Activator 3 Potently Induces Apoptosis in Multiple Myeloma Cell Lines and in Primary Human Multiple Myeloma Cells.
Authors: Tommasina Guglielmelli, Emilia Giugliano, Ilaria Defilippi, Marisa Pautasso, Roberta Merlini, Vanessa Brunetto, Giuseppe Saglio
Journal: Blood (2009)
DPP-4 Inhibitor–Related Pancreatitis: Rare but Real!
Authors: J. Hans DeVries, Julio Rosenstock
Journal: Diabetes Care (2017)

Following the U.S. Food and Drug Administration (FDA) Guidance issued in 2008 to demonstrate cardiovascular safety for the purpose of regulatory approval of new glucose-lowering agents for type 2 diabetes management, the number of placebo-controlled randomized clinical trials has increased exponentially. As previously proposed by members of the Diabetes Care editorial committee (1), these regulatory-required large cardiovascular outcome trials (CVOTs) can provide unique opportunities to learn more about the overall safety and potential off-target effects of these new drugs beyond their cardiovascular safety. Carefully conducted pooled analyses of patient-level data emanating from these CVOTs can better estimate potential adverse events that may occur infrequently or perhaps may only be seen as tenuous inconclusive signals in smaller, shorter duration, randomized controlled phase 3 trials or may emerge once the new agents are widely prescribed in clinical practice.

Indeed, one such adverse event is acute pancreatitis related to incretin-based therapies consistently noted as numerical imbalances occurring in many randomized clinical trials (2). Acute pancreatitis has been a safety issue of major controversy with conflicting reports from observational retrospective studies often based on administrative insurance and prescription claim data and/or clinical practice registries. So far, reliable assessments of the relationship between pancreatitis and dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 receptor agonists based on these observational reports have been hampered by the inherent methodological shortcomings with limitations such as confounding by indication, missing data, lag-time biases, unknown residual confounding, etc. (3). Even rigorously conducted epidemiological analyses adjusting for multiple confounders cannot provide definitive answers (4). The FDA MedWatch reporting system is another unreliable source with incomplete clinical information often influenced by the media and difficult to interpret without data on the denominator.

Large-scale CVOTs have now been reported for three DPP-4 inhibitors: saxagliptin, alogliptin, and sitagliptin (5–7). There were …
Clinicopathologic factors associated with involved margins following breast conserving surgery for invasive lobular carcinoma (ILC)
Authors: E. J. Silberfein, K. K. Hunt, K. Broglio, J. Shen, A. Sahin, H. Le-Petross, J. Oh, J. Litton, R. F. Hwang, E. A. Mittendorf
Journal: Journal of Clinical Oncology (2009)

e11528 Background: ILC is characterized by a diffusely infiltrative growth pattern making it difficult to accurately assess disease extent prior to surgical resection. This has resulted in difficulty obtaining negative margins at the time of breast conserving surgery. We evaluated patients undergoing surgery for ILC to determine if there were specific clinicopathologic factors influencing the ability to obtain negative margins. Methods: We identified 211 patients with ILC treated between 1994 and 2004. Clinical data including radiographic appearance, biopsy method, initial surgical procedure (segmental vs. total mastectomy), and use of neoadjuvant chemotherapy were noted. Pathologic data included margin status (negative (&gt;2mm), close (0–2mm), or positive), multifocality, multicentricity, ILC subtype, grade, associated LCIS or DCIS, hormone receptor status and HER2 status. Factors associated with close or positive margins were determined using univariate and multivariate analyses. Subset analysis was performed on patients whose initial surgery was segmental mastectomy. Results: 110 (52%) patients underwent total mastectomy and 101 (48%) underwent segmental mastectomy as their initial procedure. For patients undergoing segmental mastectomy, 50 (50%) had positive or close margins requiring re-excision. Patients with close or positive margins were more likely to have distortion on ultrasound (vs. mass, p=.05), to have undergone an excisional biopsy (vs. core or FNA, p=.008), and to have associated DCIS (p=.02). On multivariate analysis, only biopsy method retained significance (p = .006). Having an excisional biopsy for diagnosis was also associated with need for multiple surgeries (p &lt; .0001). Breast conserving surgery was ultimately successful in 86 patients (85%). Conclusions: The majority of patients with ILC can undergo successful breast conserving surgery. Patients with distortion rather than a mass on imaging and those with DCIS are more likely to have close or positive margins. Diagnosis by excisional biopsy makes subsequent imaging less reliable and results in the need for multiple surgeries to ensure adequate excision. No significant financial relationships to disclose.
Preliminary Phase II Study Results of BBR2778 in Combination with Cyclophosphamide, Vincristine, and Prednisone in Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma.
Authors: Raoul Herbrecht, Peter Borchmann, Martin Wilhelm, Franck Morschhauser, Georg Hess, Klaus Kutz, Silvia Comis, Bernard L. Laffranchi, Andreas Engert
Journal: Blood (2004)
CD8+CD28− in Peripheral Blood of Patients with Cutaneus T-Cell Lymphoma (CTLC) in Different Clinical Stages.
Authors: Donata M. Urbaniak-Kujda, Katarzyna L. Kapelko-Slowik, Bozena Jazwiec, Joanna Maj, Jaroslaw Dybko, Miroslaw Slowik, Dariusz Wolowiec, Irena Frydecka, Kazimierz Kuliczkowski
Journal: Blood (2007)
Effect of HMG CoA reductase inhibitors on the grade and recurrence of colonic polyps
Authors: R. Surapaneni, R. Behm, C. Wood
Journal: Journal of Clinical Oncology (2006)

1016 Background: The burden of treating colon cancer on the healthcare system is huge and screening for colonic polyps has been very effective. Colon cancer arises from colonic polyps in a significant percent of patients and preventive measures to control colonic polyps in the form of dietary interventions, NSAIDS have been looked into. But there are no studies to our knowledge that looked at the effect of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) on colon polyps. The aim of this study was to examine the effect of HMG CoA reductase inhibitors on the grade and recurrence of colonic polyps. Methods: This retrospective case control study included review of the charts of all patients at Geisinger Medical Center who had colonoscopy and polypectomy between 1998 and 2003. These patients were divided into two groups based on the use of HMG CoA reductase inhibitors. A total of 207 patients were identified of which, 60 were in statin group and 147 were in the non-statin group. Logistic regression was used to evaluate the relationships between statin use and 1) recurrence of colonic polyps and, 2) histological grade. Additionally, Cox regression was used to examine the relationship between statin use and time until colonic polyp recurrence. Results: The rate of recurrence of colonic lesions and histological grade at follow-up were not different between the two groups. However, time until recurrence (based on time until 2 nd colonoscopy) was longer in the statin group (p=0.001). This association remained after controlling for aspirin use and other characteristics of the patient (p=0.013). Conclusion: Our study suggests that HMG CoA reductase inhibitors might have a role in the secondary prevention of colonic polyps. Larger, prospective randomized studies are needed to validate this finding. [Table: see text] No significant financial relationships to disclose.
What Is New? An Update of the MLL Recombinome Including the Three Novel Partner Genes ABI2, PDS5A, and TOP3A
Authors: Claus Meyer, Mariana Emerenciano, Eva A Coenen, Eric Delabesse, Charles Herbaux, Julia Hofmann, Marry M. van den Heuvel-Eibrink, C. Michel Zwaan, Theo Dingermann, Tae Sung Park, Thomas Klingebiel, Rolf Marschalek
Journal: Blood (2011)
HEPATOBILIARY PHOSPHOLIPID TRANSLOCATER MDR3 (ABCB4) GENOTYPE IS ASSOCIATED WITH THE DEVELOPMENT OF NON-ANASTOMOTIC BILIARY STRICTURES AFTER LIVER TRANSPLANTATION
Authors: Sanna op den Dries, Carlijn I. Buis, Gerrit van der Steege, Robert J. Porte
Journal: Hepatology (2011)
Association of G6PD −202/−376 with Lower Hemoglobin Concentration but Not Increased Hemolysis in Patients with Sickle Cell Anemia.
Authors: Mehdi Nouraie, Noel S. Reading, Andrew Campbell, Caterina Minniti, Sohail R Rana, Lori Luchtman-Jones, Mark Gladwin, Gregory J Kato, Oswaldo L Castro, Josef T. Prchal, Victor R. Gordeuk
Journal: Blood (2009)
Multigene Mutational Clinical Profiling Using Next Generation Sequencing in a Cohort of 451 Patients with MDS: Impact on Clinical Outcomes
Authors: Keyur Patel, Mark Routbort, Graciela Noguera-Gonzalez, Hagop M. Kantarjian, Elias Jabbour, Gautam Borthakur, Courtney D. DiNardo, Zeev Estrov, Naval G. Daver, William G Wierda, Nitin Jain, Susan O'Brien, Marina Konopleva, Jorge E. Cortes, Naveen Pemmaraju, Yesid Alvarado, Carlos E. Bueso-Ramos, Raja Luthra, Rajesh Singh, Sherry Pierce, L. Jeffrey Medeiros, Zachary Bohannan, Xuelin Huang, Guillermo Garcia-Manero
Journal: Blood (2014)